Glycemic control in diabetic dialysis patients and the burnt-out diabetes phenomenon

Current Diabetes Reports

Volumn 12, Issue 4, 2012, Pages 432-439

  Park, Jongha ^a,b   Lertdumrongluk, Paungpaga ^a   Molnar, Miklos Z ^a,c   Kovesdy, Csaba P ^d,e   Kalantar Zadeh, Kamyar ^a,f  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b Ulsan University College of Medicine   (South Korea)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY OF VIRGINIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Burnt out diabetes; Chronic kidney disease; Diabetes mellitus; Diabetic dialysis; Glycemic control; Hemoglobin A1c; Maintenance dialysis

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

BURNT OUT DIABETES; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; REVIEW; SURVIVAL RATE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; RENAL DIALYSIS; RISK FACTORS; SURVIVAL RATE;

EID: 84865603225     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0286-3     Document Type: Review

References (55)

1. Kovesdy CP, Sharma K, Kalantar-Zadeh K. Glycemic control in diabetic CKD patients: Where do we stand? Am J Kidney Dis. 2008;52:766-77.
2. Kovesdy CP, Kalantar-Zadeh K. Enter the dragon: A Chinese epidemic of chronic kidney disease? Lancet. 2012;379:783-5.
3. USRDS. Annual Data Report: Atlas of End-Stage Renal Disease in the United States. 2011. http://www.usrds.org/atlas.asps Accessed 10 April 2012.
4. Kalantar-Zadeh K, Derose SF, Nicholas S, et al. Burnt-out diabetes: Impact of chronic kidney disease progression on the natural course of diabetes mellitus. J Ren Nutr. 2009;19:33-7.
5. Kovesdy CP, Park JC, Kalantar-Zadeh K. Glycemic control and burnt-out diabetes in ESRD. Semin Dial. 2010;23:148-56.
6. Fluckiger R, Harmon W, Meier W, et al. Hemoglobin carbamylation in uremia. N Engl J Med. 1981;304:823-7. (Pubitemid 11147484)
7. Kalantar-Zadeh K, Mehrotra R, Fouque D, Kopple JD. Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure. Semin Dial. 2004;17:445-65.
8. De Marchi S, Cecchin E, Camurri C, et al. Origin of glycosylated hemoglobin A1 in chronic renal failure. Int J Artif Organs. 1983;6:77-82. (Pubitemid 13102514)
9. Mirani M, Berra C, Finazzi S, et al. Inter-day glycemic variability assessed by continuous glucose monitoring in insulin-treated type 2 diabetes patients on hemodialysis. Diabetes Technol Ther. 2010;12:749-53.
10. Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T, et al. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care. 2009;32:1137-42.
11. Riveline JP, Hadjadj S. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes: Response to Kazempour-Ardebili et al. Diabetes Care. 2009;32:e155-6. author reply.
12. Williams ME, Lacson Jr E, Teng M, et al. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int. 2006;70:1503-9. (Pubitemid 44527322)
13. Shurraw S, Majumdar SR, Thadhani R, et al. Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis. Am J Kidney Dis. 2010;55:875-84.
14. Freedman BI, Andries L, Shihabi ZK, et al. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol. 2011;6:1635-43.
15. Peacock TP, Shihabi ZK, Bleyer AJ, et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int. 2008;73:1062-8. (Pubitemid 351543905)
16. Kumeda Y, Inaba M, Shoji S, et al. Significant correlation of glycated albumin, but not glycated haemoglobin, with arterial stiffening in haemodialysis patients with type 2 diabetes. Clin Endocrinol (Oxf). 2008;69:556-61.
17. Inaba M, Okuno S, Kumeda Y, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: Effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007;18:896-903. (Pubitemid 46434506)
18. Rubinow KB, Hirsch IB. Reexamining metrics for glucose control. JAMA. 2011;305:1132-3.
19. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362:800-11.
20. WuMS, Yu CC, Yang CW, et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant. 1997;12:2105-10.
21. Morioka T, Emoto M, Tabata T, et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care. 2001;24:909-13. (Pubitemid 33636068)
22. Mcmurray SD, Johnson G, Davis S, Mcdougall K. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis. 2002;40:566-75. (Pubitemid 34971286)
23. Oomichi T, Emoto M, Tabata T, et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: A 7-year observational study. Diabetes Care. 2006;29:1496-500. (Pubitemid 44127570)
24. Kalantar-Zadeh K, Kopple JD, Regidor DL, et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007;30:1049-55. This is a large study in which A1c is associated with mortality after adjusting possible confounders including demographics, comorbidities, anemia and nutrition. It also shows a significant prevalence of A1c level <6% in HD patients. (Pubitemid 46684623)
25. Feldt-Rasmussen B. Is there a need to optimize glycemic control in hemodialyzed diabetic patients? Kidney Int. 2006;70:1392-4. (Pubitemid 44527307)
26. Williams ME, Lacson Jr E, Teng M, et al. Extremes of glycemic control (HbA1c) increase hospitalization risk in diabetic hemodialysis patients in the USA. Am J Nephrol. 2009;29:54-61.
27. Williams ME, Lacson Jr E, Wang W, et al. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: Comparative results of traditional and time-dependent cox model analyses. Clin J Am Soc Nephrol. 2010;5:1595-601. The authors supplements their previous observation, in which A1c did not related to mortality in dialysis patients, by extending follow-up to 3 years and using time-dependent survival models. They show only extremes of glycemia are associated with inferior survival, suggesting an aggressive glycemic control is not mandatory in this population.
28. Duong U, Mehrotra R, Molnar MZ, et al. Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. Clin J Am Soc Nephrol. 2011;6:1041-8.
29. Molnar MZ, Huang E, Hoshino J, et al. Association of pretransplant glycemic control with posttransplant outcomes in diabetic kidney transplant recipients. Diabetes Care. 2011;34:2536-41.
30. Ricks J, Molnar MZ, Kovesdy CP, et al. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: A 6-year cohort study. Diabetes. 2012;61:708-15. This is a very recent, large, nationally representative study. It demonstrates a J-shaped association between A1c (or glucose) and mortality. Of noteworthy about 40% of HD patients have A1c levels <6% linking to inferior survival.
31. Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: A population-based cohort study. Arch Intern Med. 2011;171:1920-7.
32. Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial. 2000;13:4-8.
33. Dzurik R, Spustova V, Lajdova I. Inhibition of glucose utilization in isolated rat soleus muscle by pseudouridine: Implications for renal failure. Nephron. 1993;65:108-10. (Pubitemid 23241549)
34. Mccaleb ML, Izzo MS, Lockwood DH. Characterization and partial purification of a factor from uremic human serum that induces insulin resistance. J Clin Invest. 1985;75:391-6. (Pubitemid 15143477)
35. Schmitz O. Insulin-mediated glucose uptake in nondialyzed and dialyzed uremic insulin-dependent diabetic subjects. Diabetes. 1985;34:1152-9. (Pubitemid 16218520)
36. Friedman JE, Dohm GL, Elton CW, et al. Muscle insulin resistance in uremic humans: Glucose transport, glucose transporters, and insulin receptors. Am J Physiol. 1991;261:E87-94.
37. Akmal M, Massry SG, Goldstein DA, et al. Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J Clin Invest. 1985;75:1037-44. (Pubitemid 15115274)
38. Mak RH, Bettinelli A, Turner C, et al. The influence of hyperparathyroidism on glucose metabolism in uremia. J Clin Endocrinol Metab. 1985;60:229-33. (Pubitemid 15129564)
39. Ikizler TA. Effects of glucose homeostasis on protein metabolism in patients with advanced chronic kidney disease. J Ren Nutr. 2007;17:13-6. (Pubitemid 46014450)
40. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase-and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000;105:311-20. (Pubitemid 30094451)
41. Lee SW, Dai G, Hu Z, et al. Regulation of muscle protein degradation: Coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol. 2004;15:1537-45. (Pubitemid 38679678)
42. Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73:391-8. (Pubitemid 351186278)
43. Cano N. Bench-to-bedside review: Glucose production from the kidney. Crit Care. 2002;6:317-21. (Pubitemid 34863698)
44. Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am. 1989;18:103-21. (Pubitemid 19058104)
45. Heaton A, Taylor R, Johnston DG, et al. Hepatic and peripheral insulin action in chronic renal failure before and during continuous ambulatory peritoneal dialysis. Clin Sci (Lond). 1989;77:383-8. (Pubitemid 19237080)
46. Grodstein GP, Blumenkrantz MJ, Kopple JD, et al. Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int. 1981;19:564-7. (Pubitemid 11120902)
47. Mamoun AH, Anderstam B, Sodersten P, et al. Influence of peritoneal dialysis solutions with glucose and amino acids on ingestive behavior in rats. Kidney Int. 1996;49:1276-82. (Pubitemid 26166403)
48. Walls EK, Koopmans HS. Differential effects of intravenous glucose, amino acids, and lipid on daily food intake in rats. Am J Physiol. 1992;262:R225-234.
49. Von Baeyer H, Gahl GM, Riedinger H, et al. Adaptation of CAPD patients to the continuous peritoneal energy uptake. Kidney Int. 1983;23:29-34. (Pubitemid 13148171)
50. Sharma R, Rosner MH. Glucose in the dialysate: Historical perspective and possible implications? Hemodial Int. 2008; 12:221-6. (Pubitemid 351494275)
51. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545-59. (Pubitemid 351831356)
52. Patel A, Macmahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72. (Pubitemid 351831357)
53. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002; 287:2563-2569.
54. Fioretto P, SteffesMW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339:69-75. (Pubitemid 28304880)
55. Kalantar-Zadeh K. A1c remains gold standard outcome predictor in diabetic dialysis patients. Diabetes Care, July 2012 doi:10.2337/ dc12-0483.